Table 2.
Disease at baseline prior to chemotherapy
| PCI Not Received (N=44) |
PCI Received (N=41) |
Total (N=85) |
p value | |
|---|---|---|---|---|
| No. of sites | 0.6367 | |||
| Median | 4.5 | 5.0 | 5.0 | |
| Range | (1–10) | (2–8) | (1–10) | |
| No. of sites | 0.3615 | |||
| 1–2 | 4 (9.1%) | 1 (2.4%) | 5 (5.9%) | |
| 3–10 | 40 (90.9%) | 40 (97.6%) | 80 (94.1%) | |
| Sites specific | ||||
| Primary lung | 41 (93.2%) | 38 (92.7%) | 79 (92.9%) | 1.0000 |
| Contralateral lung | 10 (22.7%) | 5 (12.2%) | 15 (17.6%) | 0.2601 |
| Ipsilateral hilar nodes | 24 (54.5%) | 26 (63.4%) | 50 (58.8%) | 0.5091 |
| Contralateral hilar nodes | 7 (15.9%) | 7 (17.1%) | 14 (16.5%) | 1.0000 |
| Mediastinal nodes | 32 (72.7%) | 33 (80.5%) | 65 (76.5%) | 0.4509 |
| Ipsilateral supraclavicular/scalene nodes | 7 (15.9%) | 10 (24.4%) | 17 (20.0%) | 0.4188 |
| Contralateral supraclavicular/scalene | 5 (11.4%) | 5 (12.2%) | 10 (11.8%) | 1.0000 |
| Pleura | 5 (11.4%) | 7 (17.1%) | 12 (14.1%) | 0.5405 |
| Liver | 22 (50.0%) | 22 (53.7%) | 44 (51.8%) | 0.8290 |
| Adrenals | 9 (20.5%) | 5 (12.2%) | 14 (16.5%) | 0.3860 |
| Bone | 21 (47.7%) | 17 (41.5%) | 38 (44.7%) | 0.6636 |
| Other nodal | 11 (25.0%) | 10 (24.4%) | 21 (24.7%) | 1.0000 |
| Other sites | 8 (18.2%) | 9 (22.0%) | 17 (20.0%) | 0.7879 |
PCI, prophylactic cranial irradiation.